Prolonged Use of Progestogens May Raise Risk for Intracranial Meningioma
By Elana Gotkine HealthDay Reporter
FRIDAY, March 29, 2024 -- Prolonged use of medrogestone, medroxyprogesterone acetate, and promegestone is associated with an increased risk for intracranial meningioma, according to a study published online March 27 in The BMJ.
Noémie Roland, M.D., M.P.H., from the EPI-PHARE Scientific Interest Group in Saint-Denis, France, and colleagues conducted a national case-control study involving 108,366 women overall to examine the risk for intracranial meningioma associated with use of selected progestogens. Cases included 18,061 women living in France who had intracranial surgery for meningioma between Jan. 1, 2009, and Dec. 31, 2018; each case was matched to five controls (90,305 controls).
The researchers found that the risk for meningioma was increased with use of medrogestone (0.2 percent among cases versus 0.1 percent among controls; odds ratio, 3.49), medroxyprogesterone acetate (injectable; 0.05 versus 0.01 percent; odds ratio 5.55), and promegestone (0.5 versus 0.2 percent; odds ratio, 2.39). The excess risk was driven by use for one year or longer. No excess risk for intracranial meningioma was seen for progesterone, dydrogesterone, or levonorgestrel intrauterine systems. Due to the small number of people receiving dienogest or hydroxyprogesterone, no conclusions could be drawn.
"Future studies should further clarify the association between the duration of use and risk for the progestogens studied, and extend the discussion of meningioma risk to dienogest and hydroxyprogesterone," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
ASTRO: Many Patients Have Cognitive Recovery After Brain Radiotherapy
FRIDAY, Oct. 4, 2024 -- Many patients with brain metastases who experience initial neurocognitive failure (NCF) following brain radiation therapy demonstrate recovery, with...
Treatment of CNS Tumors in Childhood Slows Academic Readiness
WEDNESDAY, Aug. 28, 2024 -- Treatment of central nervous system (CNS) tumors in early childhood is associated with slowed development of academic readiness, which predicts distal...
FDA Approves Voranigo for Grade 2 Astrocytoma or Oligodendroglioma
FRIDAY, Aug. 9, 2024 -- The U.S. Food and Drug Administration has approved Voranigo (vorasidenib) for grade 2 astrocytoma or oligodendroglioma with a susceptible mutation. The...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.